Working… Menu
Trial record 1 of 1 for:    NCT01570205
Previous Study | Return to List | Next Study

Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01570205
Recruitment Status : Completed
First Posted : April 4, 2012
Last Update Posted : April 4, 2012
Information provided by (Responsible Party):
Xigen SA

Brief Summary:
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers

Condition or disease Intervention/treatment Phase
Inflammation Drug: XG-102 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Male Volunteers in a Randomized, Double Blind, Placebo Controlled, Dose Escalating Phase I Study
Study Start Date : July 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : February 2012

Arm Intervention/treatment
Experimental: XG-102 10 µg/kg Drug: XG-102
single intravenous infusion

Experimental: XG-102 40 µg/kg Drug: XG-102
single intravenous infusion

Experimental: XG-102 80 µg/kg Drug: XG-102
single intravenous infusion

Placebo Comparator: placebo Drug: XG-102
single intravenous infusion

Primary Outcome Measures :
  1. Safety of XG-102 [ Time Frame: 1 month ]
    Safety of XG-102 assessed by incidence and intensity of adverse events, clinical laboratory evaluations, vital signs, ECG, phaysical examination, ocular examination

Secondary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: 16 time-points up to 24 hours ]
    Pharmacokinetic profile will be evaluated by determination of Cmax, AUC, Half-life, Clearance , Volume of distribution

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male volunteers
  • Age ≥ 18 to ≤ 45 years
  • BP: 100 - 150 mm Hg systolic, 50 - 95 mm Hg diastolic and pulse rate: 50 - 100 bpm.
  • Body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 100 kg range.
  • Are able to communicate and co-operate with the Investigator and his/her staff
  • Healthy on the basis of medical history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12 lead ECG readings
  • Written informed consent obtained
  • Male subjects with partners of childbearing potential have to use adequate contraception during, and for at least the four weeks after administration of study medication.

Exclusion Criteria:

  • Heavy smokers, i.e. more than 10 cigarettes per day
  • Participation in a clinical trial during the previous 4 weeks
  • Loss of 500 mL blood or more during the 3 month period before the screening visit of the study
  • Existence of any surgical or medical condition which might relevantly interfere with the subject safety, the distribution, metabolism or excretion of the drug or the study assessments, i.e. impaired renal or hepatic function, diabetes mellitus, thyroid function abnormalities including abnormal thyroid hormone values in the Screening evaluation, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
  • History of alcohol or drug abuse in the last 3 years.
  • Positive results of the drug Screening.
  • Clinically significant abnormal laboratory values at the Screening or baseline evaluation.
  • A history of any serious adverse reaction or hypersensitivity to any drug or other medicines
  • Presence or history of any allergy requiring acute or chronic treatment (seasonal allergic rhinitis which requires no treatment may be tolerated).
  • Positive results from serology examination for HBV, HCV, HIV or tuberculosis
  • History of serious mental disorders.
  • Need of any prescription medication within 30 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study.
  • Volunteers who are unwilling to comply with the provisions of this protocol
  • Symptoms of a significant (upon Investigator's medical judgment) somatic or mental illness in the two week period preceding drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01570205

Layout table for location information
Covance Clinical Research
Allschwil, BS, Switzerland, 4123
Sponsors and Collaborators
Xigen SA
Layout table for investigator information
Principal Investigator: Michael Seiberling, MD Covance Clinical Research
Layout table for additonal information
Responsible Party: Xigen SA Identifier: NCT01570205    
Other Study ID Numbers: SDD-1002-024
First Posted: April 4, 2012    Key Record Dates
Last Update Posted: April 4, 2012
Last Verified: April 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes